A Phase 2 interventional study of Etanercept and Autoinjector in Rheumatoid Arthritis, sponsored by Samsung Bioepis Co., Ltd.. Completed at 1 site in Poland. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-10-13.
Sponsored by Samsung Bioepis Co., Ltd. · Phase 2, Interventional, and Other
A study comparing the usability of the Autoinjector and Pre-filled Syringe of SB4 in Subjects with Rheumatoid Arthritis.
3,554 studies on the registry are indexed under Arthritis; 318 are open to participants now.
This study's enrollment of 50 is below the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →Samsung Bioepis Co., Ltd. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
SB4 (etanercept) 50 mg/mL
Drug: Etanercept · Device: Autoinjector
Etanercept PFS and Autoinjector
Autoinjector
The change in Injection site pain score at immediately post injection (within 1 minute)
The change in injection site pain score at immediately post injection (within 1 minute) using an 11-point visual numeric scale
Time frame: at Week 1 and Week 3
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Samsung Bioepis Co., Ltd.